☆ 4.5 Article

Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Jesus San-Miguel et al.

Summary: The subcutaneous formulation of daratumumab with rHuPH20 in the PAVO study showed good tolerability and efficacy similar to intravenous daratumumab. The concentrated pre-mixed co-formulation (DARA SC) achieved comparable daratumumab trough concentrations as intravenous dosing, with a lower infusion-related reaction rate. Ongoing studies are further investigating the use of DARA SC in the treatment of multiple myeloma and other conditions.

HAEMATOLOGICA (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology

Sonoko Kawakatsu et al.

Summary: This review explores different approaches to mitigate confounding effects for monoclonal antibodies in oncology, highlighting the potential utility of tumour growth inhibition-overall survival modelling. It suggests considering more dose levels in earlier trials as an alternative to single dose level trials in oncology drug development programmes.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Review Health Care Sciences & Services

Targeted Therapies for Multiple Myeloma

Christopher Chang-Yew Leow et al.

Summary: Despite advancements in therapies such as proteasome inhibitors and immunomodulatory drugs, multiple myeloma remains a challenging and relapsing disease with no cure in sight. Over the past decade, novel drugs targeting essential cellular proteins and anti-apoptotic, ribosomal, and nuclear export proteins have emerged as potential treatments against malignant plasma cells.

JOURNAL OF PERSONALIZED MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets

Stephen P. H. Alexander et al.

Summary: The Concise Guide to PHARMACOLOGY 2021/22 provides concise overviews of nearly 1900 human drug targets, with emphasis on selective pharmacology. It also includes links to an open access knowledgebase for more detailed information. Additionally, the guide discusses six main areas of focus for drug targets and pharmacological tools.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Review Genetics & Heredity

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hamza Hassan et al.

Summary: Multiple myeloma is a heterogeneous disease characterized by clonal plasma cell proliferation and genomic instability. Next-generation sequencing has allowed researchers to uncover the complex genomic landscape of the disease. These genomic aberrations impact patient outcomes and survival, serving as new markers that could be integrated into prognostic models.

APPLICATION OF CLINICAL GENETICS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Man Melody Luo et al.

Summary: This study reported the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous formulation of daratumumab (DARA) and showed similar PK profiles between subcutaneous and intravenous DARA, along with consistent exposure-response relationships. The results support the use of DARA 1800-mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg, with further investigation needed to determine the potential relationships between drug dose, body weight, and infection rates.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Hematology

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z. Usmani et al.

BLOOD (2019)

添加到收藏夹

Article Biochemical Research Methods

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Homer C. Adams et al.

CYTOMETRY PART A (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetics of Monoclonal Antibodies

Josiah T. Ryman et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

X. S. Xu et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis

C. Liu et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Review Hematology

Treatment of relapsed and refractory multiple myeloma

Pieter Sonneveld et al.

HAEMATOLOGICA (2016)

添加到收藏夹

Article Immunology

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking

Marije B. Overdijk et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Review Hematology

Treatment of relapsed and refractory multiple myeloma

Pieter Sonneveld et al.

HAEMATOLOGICA (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk et al.

MABS (2015)

添加到收藏夹

Meeting Abstract Hematology

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren et al.

BLOOD (2014)

添加到收藏夹

Article Immunology

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers et al.

JOURNAL OF IMMUNOLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.